Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma - Trial NCT06304350
Access comprehensive clinical trial information for NCT06304350 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tongji University and is currently Recruiting. The study focuses on Esophageal Cancer. Target enrollment is 25 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tongji University
Timeline & Enrollment
Phase 2
Feb 17, 2024
Dec 31, 2026
Primary Outcome
Pathological complete remission (pCR)
Summary
This study is a prospective, single center, open label, single arm clinical study. Select
 resectable locally advanced (cT3-4aN0M0, cT1-3N1-2M0, cII/III stage) esophageal cancer with
 pathological diagnosis of squamous cell carcinoma for inclusion, receive pembrolizumab
 combined with platinum containing dual drug (albumin paclitaxel+carboplatin) treatment for 2
 courses, and undergo surgery. After surgery, continue pembrolizumab immunotherapy. Using pCR
 as the main endpoint of the study
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06304350
Non-Device Trial